Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics
RIGL Price/Volume Stats
| Current price | $13.75 | 52-week high | $17.30 |
| Prev. close | $13.70 | 52-week low | $7.12 |
| Day low | $13.50 | Volume | 64,400 |
| Day high | $14.04 | Avg. volume | 145,330 |
| 50-day MA | $11.41 | Dividend yield | N/A |
| 200-day MA | $11.80 | Market Cap | 241.42M |
RIGL Stock Price Chart Interactive Chart >
Rigel Pharmaceuticals, Inc. (RIGL) Company Bio
Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.
Latest RIGL News From Around the Web
Below are the latest news stories about RIGEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RIGL as an investment opportunity.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock Catapults 44% Though Its Price And Business Still Lag The IndustryRigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders would be excited to see that the share price has had a great... |
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are up 20% this past week, but still in the red over the last three yearsThis month, we saw the Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) up an impressive 56%. But that is small recompense... |
Best Momentum Stock to Buy for December 8thBRSP and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2023. |
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other CancersRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. |
Best Momentum Stocks to Buy for November 22ndBWAY, RIGL and BROS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 22, 2023. |
RIGL Price Returns
| 1-mo | 13.54% |
| 3-mo | N/A |
| 6-mo | -5.17% |
| 1-year | 28.50% |
| 3-year | -64.74% |
| 5-year | -19.59% |
| YTD | -5.17% |
| 2023 | -3.33% |
| 2022 | -43.40% |
| 2021 | -24.29% |
| 2020 | 63.55% |
| 2019 | -6.96% |
Continue Researching RIGL
Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...